Background Chronic fatigue is a feature in a subset of women successfully treated for breast cancer but is not well characterised. This study examines differences in objective cognitive function, activity levels and sleep in disease-free women who do and do not meet criteria for cancer-related fatigue syndrome (CRFS). Methods Women between 3 months and 2 years after completion of any primary therapy were recruited from a cancer centre follow-up clinic. On the basis of a diagnostic semi-structured interview they were classifi ed as being CRFS cases or non-fatigued controls. Participants underwent objective cognitive testing using a computerised battery, wore an activity monitor for 1 week and completed quality of life and fatigue questionnaires. Results 114 women were recruited (69 controls and 45 CRFS cases). There were signifi cant differences between groups on fatigue, mood, sleep and quality of life scores, and in objective cognitive testing (tests of sustained attention, reaction time and verbal memory all p<0.03). There was an overall difference in daytime activity (p=0.03) from actigraphy recordings. There were no differences on objective measures of sleep or in routine laboratory measures. Conclusions Our preliminary results suggest that disease-free women with CRFS after successful breast cancer treatment have signifi cantly lower subjective quality of life and mood. Additionally, objective cognitive impairment in certain domains may play an important role in the subjective manifestation of these symptoms. There is also objective evidence on actigraphy of differing levels of activity. The subjective sleep disturbance and higher prevalence of insomnia do not correlate with objective measures.
INTRODUCTION
Two thirds of women diagnosed with breast cancer today are likely to survive for at least 20 years. 1 As a result more women are living with the longerterm side-effects of treatment. These can include neurocognitive changes, 2 3 sleep disturbance, 4 quality of life impairment and persistent fatigue. 5 Of the many symptoms associated with cancer and its treatment, fatigue is probably the most under-recognised and poorly managed. 6 We have previously undertaken a systematic review of the literature regarding the prevalence of fatigue in breast cancer survivors (BCS). 7 Many of the early studies of fatigue in cancer populations were limited by the use of poorly validated assessment instruments and the lack of a coherent defi nition of cancer-related fatigue syndrome (CRFS). 8 However, in 1998 Cella and colleagues 9 proposed the introduction of diagnostic criteria for CRFS, which have now been successfully applied in a number of clinical studies. [10] [11] [12] [13] [14] These criteria are based on similar principles to those used to diagnose patients with chronic fatigue syndrome (CFS). 15 Most recently, our own group rigorously applied the diagnostic criteria to BCS between 3 months and 2 years after completion of treatment. We found the prevalence of CRFS to be 30%. 16 CRFS is a clinical diagnosis and as such relies on the subjective reports of patients. Broadly speaking, patients' complaints of fatigue relate to either decrements in motor performance (physical fatigue) or impaired cognitive abilities (mental fatigue). Unfortunately, the same term can be used to describe both an objective physical or mental decrement in performance and a subjective mental state. Both types of fatigue are usually found to a greater or lesser extent in the same individual. However, there is no direct correspondence between the two phenomena. It is quite possible to feel extremely subjectively fatigued but to perform relatively normally on objective tests of physical or mental functioning.
However, patients' subjective complaints of physical fatigue relate to changes in the activities of daily living, mobility and the need for daytime naps. Unobtrusive objective monitoring is required to investigate these phenomena and studies have been performed using actigraphy (real-time activity monitoring). Overall, the data from several studies 17 18 suggest that there is a strong correlation between changes in subjective fatigue and actigraphy data measures. The most consistent correlations occur between fatigue measures and disruption of sleep quality. However, the limitations of and variations in data collection mean these fi ndings need further confi rmation. In particular, these data have been recorded in patients on treatment and linked to sleep disturbances and have not adequately assessed the level of daytime fatigue. The exception to this was a study by our group 16 in which, contrary to expectation, we found no signifi cant differences in activity levels in a population of fatigued BCS compared to nonfatigued controls.
Several researchers have investigated cognitive changes in cancer survivors. Recent systematic reviews 19 and a meta-analysis 3 concluded that there is some evidence of objective declines in cognitive function (particularly verbal memory and executive function) following chemotherapy, but only one previous study has attempted to relate these objective fi ndings to subjective complaints of fatigue. 20 However, the authors did not use the diagnostic criteria 9 and only employed a limited range of cognitive testing.
The primary aim of this study was to examine differences in objective measures of cognition (specifi cally focusing on previously identifi ed cognitive domains that were affected) and in physical activity in women who did or did not meet the criteria for CRFS. All patients who were clinically and radiologically diseasefree between 3 months and 2 years after the end of their primary treatment (of any modality) were invited to participate. Concurrent hormone use was allowed.
MATERIALS AND METHODS

BCS
Those patients with signifi cant cognitive impairment, a psychiatric history or medical co-morbidities on notes review or initial discussion with the researcher (OM) were excluded from entering the study (12 women in total). This was a pragmatic decision as these women were not eligible for the complete study.
Eligible women were identifi ed from the clinic list 14 days before their appointment and received an introductory letter and an information sheet by post. Women who declined to participate in the study were asked if they would be willing to complete a short fatigue questionnaire.
Assessment 1
Women who consented to participate were invited to an initial consultation in a designated research facility and completed the following interviews and actigraphy.
Diagnostic Interview for Cancer-Related Fatigue
This interview determines whether the participant meets the four criteria for a diagnosis of CRFS 9 : criterion A-the presence of 2 weeks of signifi cant fatigue in the preceding month and the presence of at least fi ve out of nine other fatiguerelated symptoms; criterion B-the fatigue has a signifi cant effect on work or self-care; criterion C-the fatigue symptoms are a consequence of cancer or cancer therapy; and criterion D-the symptoms are not primarily a consequence of a comorbid psychiatric disorder. The fi nal criterion can be assessed clinically, but the most robust method is to use a contemporaneous psychiatric interview. Participants with a signifi cant psychiatric history which was felt to be contributing to fatigue were excluded.
Structured Clinical Interview for the DSM-IV (SCID)
The Structured Clinical Interview for the DSM-IV (SCID) provides a method for obtaining Diagnostic and Statistical Manual (DSM)-IV diagnoses. The procedure has been successfully used in previous studies examining CRFS 11 12 and by our group. 16 All interviews were conducted by the same person (OM). The SCID can be administered by a non-psychiatrist. OM was trained in administration and supervised by a consultant liaison psychiatrist. The average administration time was 30 min.
Other questionnaires
All women were also asked to complete the following questionnaires:
(1) Functional Assessment of Cancer Therapy (FACT-F). This is a 13-item questionnaire to measure fatigue 21 in cancer and has been widely used in cancer treatment trials. 22 (2) The Chalder Fatigue Scale (FS). 23 This is an 11-item questionnaire to measure fatigue. It was originally developed in non-cancer patients but has been extensively used in a number of studies in cancer. 24 29 It includes items on breast and arm symptoms and systemic treatment effects. (7) The 7-item Insomnia Severity Index (ISI). 30 This scale has previously been validated in a breast cancer population. 31 The seven items in this scale were combined with two additional sleep related questions to determine if insomnia diagnostic criteria were met:
▶ During the past month how many nights per week have you taken more than 30 min to fall asleep?
▶ During the past month how many nights per week were you awake for more than 30 min?
A diagnosis of insomnia syndrome was made if one of the above two features was present on more than three nights per week on average, there was signifi cant distress as scored on the ISI and/or fatigue or daytime somnolence was present. It took 20 min on average to administer these questionnaires and conduct the CRFS interview. An initial appointment time of an hour was made and potential participants were made aware of this time requirement.
Actigraphy
After completion of the questionnaires and interview, participants were asked to wear an Actiwatch AW4 (CamNtech, Cambridge, UK) for a period of 7 days and nights. The associated software and sleep algorithm 32 allows for the determination of selected measures of activity, sleep and circadian rhythm (over a 7-day average). A predetermined 12 h timeframe is used to defi ne daytime (light) activity: 06:00 to 18:00 h. The night-time activity period (dark) is defi ned as 18:00 to 06:00 h. The participants used an event marker on the watch to record their own individualised sleep patterns. This was recorded as the time entering and exiting bed overnight and did not include naps.
Assessment 2
Participants underwent objective cognitive testing using a predetermined computerised battery approximately 1 week later (CANTABeclipse, Cambridge Cognition, Cambridge, UK). The procedure uses a touch screen computer (Slimbook P210; PaceBlade, Amersfoort, The Netherlands) and press pad. It consists of seven different tests designed to assess the cognitive domains thought to be affected by previous breast cancer treatment. 19 This computerised battery has been previously used in a longitudinal study of cognitive changes after breast cancer treatment. 33 The procedure takes 45 min to complete and was administered by one of the authors (OM).
The tests and cognitive domains studied are listed below:
Paired Associates Learning (PAL; visuospatial ability 
Statistical considerations
The power calculation was based on an estimated sample size of 96 women. With 48 cases and 48 controls, the study would have had 80% power to detect a 0.57 (medium) betweengroup effect size on questionnaire and objective monitoring data at a 5% signifi cance level. Since this was an exploratory and hypothesis generating study, no correction was made for multiple analyses. The between-group analysis was conducted using t tests with comparisons between mean scores.
RESULTS
Due to time and resource constraints, recruitment of fatigued patients terminated slightly early with 45 of an expected 48 patients recruited. However, the number of control subjects was larger than required. A total of 114 women completed the study (69 controls and 45 cases of CRFS). Non-participants (NP=102) were asked to complete the Chalder fatigue questionnaire and ethics approval was obtained to collect anonymised demographic and treatment data from these women. The main reasons for non-participation were cited as work (28%) or the need for extra visits (32%), while 12% mentioned other medical problems and the remainder either had 'had enough' or did not want to think about their cancer (28%). The NP had a signifi cantly lower fatigue score (10.7 vs 13.1; p=0.04) and were older (62 years vs 57 years; p=0.005) than the participants. There were no differences on treatment variables, stage at diagnosis or time since diagnosis.
Cases versus controls
The overall prevalence of CRFS was 39% (45/114) . A between-group comparison for all data is shown in tables 1-5 ( There were no signifi cant differences in treatment variables between groups (table 1) .
There was a signifi cantly higher prevalence of oestrogen receptor negative tumours in the control group. There was no difference in the percentage of non-white participants between groups.
There were signifi cant differences in the levels of fatigue, mood disturbance and quality of life. There were also a number of differences in symptom subscales on both the EORTC QLQ-30 and BR23 (table 2) .
The prevalence of insomnia syndrome was signifi cantly higher in the CRFS group (44% vs 16%; p=0.001).
The routine laboratory variables (table 3) , measured to exclude any gross metabolic disturbance, did not show any signifi cant differences between groups.
The actigraphy data (table 4) which provided a measure of sleep, activity and circadian rhythm, demonstrated some differences. There was a minor difference in sleep with the control group actually having signifi cantly shorter sleep bouts. However, there were no differences in the major sleep parameters (overall time or quality). There were signifi cant differences in average daytime activity and duration of daytime (light) activity.
The cognitive data (table 5) demonstrated subtle but important differences between the groups. Signifi cant differences 
DISCUSSION
This study is the fi rst to objectively characterise cognitive differences between a rigorously defi ned group of cases of CRFS and a group of non-fatigued BCS. We found no differences in sleep actigraphy despite a much higher prevalence of insomnia 
Sleep effi ciency (%) is time asleep (as per algorithm) divided by total time in bed.
Sleep latency is time in bed before algorithm records the subject being asleep. Average value of epoch intensity (24 h period): the recording is converted to and analysed as a cosine wave around a zero point. Difference in maximum and minimum in activity corresponds to the difference between the peak and trough of the cosine wave.
Interdaily stability is a measure of consistency in daily activity over 7 days. Interdaily variability is a measure of fragmentation of periods of rest and activity; normal value are <1 and calculated over 7 days. L5 indicates the 5 h of calculated lowest activity over the 7-day average. M10 indicates the 10 h of calculated greatest activity over the 7-day average. Relative amplitude is a measure of the difference between L5 and M10 and thus an indication of overall level of activity over the 7-day period. CRFS, cancer-related fatigue syndrome.
syndrome in the CRFS group. However, mean daytime activity was lower in the CRFS group. These fi ndings raise important questions about the nature of CRFS and its relationship to objective defi cits in activity and cognition. The strengths of this study are the tight categorisation of post-treatment fatigue in BCS and the extensive cognitive and activity testing. However, the sample size is small and it is only a single centre study. The multiple analyses may have led to type I errors. This was a hypothesis generating study and was underpowered to detect all the identifi ed differences between the groups, so the discussion and conclusions should be interpreted in that context. However, we feel these are interesting data and are further validated when placed in the context of previous fi ndings.
The domains in which cognitive dysfunction occurs are the same as identifi ed in previous reviews of breast cancer patients. 19 The areas of executive function, processing speed and verbal memory are important for day-to-day tasks and may explain why these are associated with the subjective sensation of mental fatigue. Similar fi ndings were found in a comparative study between subjects with CFS and cancer fatigue 34 but not in a study comparing fatigued and non-fatigued BCS. 20 However, in the latter study it should be noted that the 'fatigued' BCS group were defi ned using a cut-off on a continuous fatigue scale (rather than using a case-based defi nition) and the cognitive testing only included measures of concentration and reaction time (rather than the more comprehensive battery of tests employed in the current study). The authors failed to fi nd differences between the fatigued and the non-fatigued group on objective cognitive testing. The objective evidence of cognitive impairment that we identifi ed in this study appears to be consistent with the questionnaire data. The Chalder Fatigue Scale and the QLQ-30 both assess perceived cognitive impairment, and the scores on both of these questionnaires were signifi cantly worse in the CRFS group.
One limitation of the cognitive assessments undertaken in this study was that they were only recorded at the end of treatment and were not measured prospectively from baseline. However, we were not specifi cally examining cognitive change per se following treatment but comparing CRFS and matched controls. The purpose was to identify potential cognitive defi cits in the CRFS group. The exclusion of psychiatric co-morbidities reinforces the hypothesis that CRFS is associated with a defi ned set of cognitive defi cits that are unrelated to mood disturbance. The underlying mechanism of cognitive dysfunction is unclear and may be related to an increase in circulating infl ammatory cytokines 35 but seems unlikely to be related to a gross hypothalamic pituitary axis disturbance. 36 Functional imaging studies in this population would help to further elucidate the mechanism. The association between subjective fatigue and objective cognitive defi cits is also interesting in relation to the fi nding that psychostimulants can reduce cancer fatigue during treatment. 37 However, they are unlikely to be suitable for longer term use in BCS 38 because of concerns related to adverse effects and the risk of addiction.
The higher prevalence of insomnia syndrome in the CRFS group was linked to higher scores on the ISI. However, this subjective perception of diffi culty with sleeping did not correlate with objective actigraphy measures of sleep. While 44% of CRFS meet the criteria for insomnia syndrome, they are clearly two separate entities and CRFS cannot be explained by sleep disturbances alone. This fi nding is supported by data from an intervention trial for insomnia that improved sleep but not fatigue. 39 We found signifi cant differences between groups with respect to objective activity data. This is in keeping with a recent study 40 in breast cancer but in confl ict with our earlier fi ndings. 16 The reason for the disparity is unclear but may be due to the different actigraph used and associated analysis algorithm. The differences were seen in the average epoch score (a measure of movement intensity) and in the level of daytime activity. These data confi rm that patients who fulfi l the criteria for CRFS, as well as being subjectively more fatigued, also have evidence of decreased physical activity. The decreased activity may be a direct consequence of feeling subjectively fatigued, or the decreased activity may arise fi rst (due to a variety of causes) and may be a causative factor in exacerbating or perpetuating the subjective fatigue that these patients experience. 41 One way to disentangle these phenomena would be to undertake a longitudinal study to assess both subjective and objective manifestations of fatigue and to trace the temporal relationships between them. 40 The authors of the study 40 did not use diagnostic criteria to measure fatigue. The theory that, whatever the cause of the initial fatigue, it is perpetuated by physical deconditioning and decreased activity probably explains why exercise is reported to be an effective treatment for cancer related fatigue. 42 It is likely, however, that the effects of exercise are relatively non-specifi c (exercise reduces fatigue even in healthy individuals) and this explains the relatively small effect size for exercise interventions in cancer populations.
In a previous study in BCS we found the prevalence of CRFS to be 30% 16 and this general fi gure was supported by the results of a systematic review. 7 The prevalence of 39% for CRFS that we found in this study although slightly higher than previous A´ is a probability score of how good a participant is at detecting sequences, correct rejection is the number of times a false sequence is ignored between correct ones and the mean latency is the time of response between the end of a sequence and the participant pressing the button. VRM: Verbal Recognition Memory (verbal information under free recall and forced choice recognitions). There are two outcomes: free recall number of correct words and a forced choice correct total (yes/no as to whether word was in the original list). CRFS, cancer-related fatigue syndrome.
estimates is broadly in keeping with these fi gures and may be explained by the fi nding that the non-participant group were signifi cantly less fatigued 16 than the study sample. A prevalence of 30-39% represents a sizeable percentage of women who have successfully completed treatment for breast cancer and potentially translates into a large absolute number of BCS. This emphasises that it is important to recognise and treat fatigue. The widespread differences in questionnaire data and levels of other symptoms are in keeping with previous studies. 12 We found that the CRFS group had a higher level of mood disturbance despite the exclusion of patients with specifi c psychiatric diagnoses. It is possible that sub-threshold mood disturbance contributes to CRFS. However fatigue and depression should be regarded as separate entities. 43 There are some important negative fi ndings in this study. There were no signifi cant differences in any of the routine laboratory tests. While fatigue may be linked to anaemia during chemotherapy, 44 this does not appear to be the case in BCS. There is also no link to thyroid disturbances. We had postulated that serum magnesium levels may be contributory but this was not found to be the case.
There were also no differences in treatment or demographic variables between groups. This is consistent with a critical appraisal 45 in which the authors found very limited associations between fatigue and these variables.
The clinical signifi cance of these fi ndings reinforces the importance of identifying women who have or are at risk of developing CRFS. This should be incorporated into routine practice and might include counselling on potential cognitive and sleep changes. These problems might be diminished with simple information giving at the start of treatment, 46 which would in keeping with the Department of Health survivorship strategy. 47 However, we are not able to recommend any particular treatment strategy at present in this group. 7 In conclusion, we have found that a signifi cant minority of women successfully treated for breast cancer meet the criteria for CRFS. This group is characterised by subjective poly-symptomology. There are important differences between the groups with objectively lower cognitive function and daytime activity in the CRFS group that need further confi rmation with a larger sample size. Future work should examine this relationship longitudinally, possibly within a quality of life arm of a treatment trial. Correlation with levels of cytokines and/or functional imaging would be helpful to further characterise this group. The overall aim should be to design more targeted treatments to manage this problematic syndrome.
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